Cellectis Stock Surges 20.2% Over the Week
The biotechnology company's stock ended the week at €3.60, up from €2.995 on Monday, marking a 20.2% increase over five trading days. This surge starkly contrasts with the general decline in French indices, with both the CAC 40 and SBF 120 falling by 1.7% over the same period. Trading volumes were particularly high on Wednesday, with more than 2.2 million shares traded, representing an unusual peak of activity for this small-cap stock.
Significant Early Week Gains
The increase was concentrated in the first three days of the week, with the price reaching a peak of €3.88 on Wednesday before stabilizing around €3.60 at the end of the period. This upward momentum is part of a remarkable underlying trend, with a three-month increase of 168.7% and a one-year rise of 87.7%, performances that far exceed those of the CAC 40, which only rose by 4.7% over twelve months. The monthly volatility of the stock, measured at 41.3%, reflects the amplitude of price movements and indicates a high-risk profile typical of biotechnology stocks in the clinical development phase. This rebound occurs as Cellectis presented its advances in gene therapy at the annual congress of the European Society of Gene and Cell Therapy (ESGCT), held in Seville from October 7 to 10. The company unveiled two scientific studies on innovative technologies: one on the use of single-strand circular DNA (CssDNA) as a non-viral vector for editing hematopoietic stem cells, and the other on the safety analysis of TALE base editors (TALEB). The data presented show that the CssDNA approach achieves high gene insertion rates and better cell grafting compared to traditional AAV viral vectors, while the study on TALEB revealed no evidence of off-target editing in the nuclear genome of primary T cells.
Technical Breakthroughs and Indicators
Technically, breaking through the resistance level at €3.88 on Wednesday was a strong signal, even though the stock slightly fell below it to close the week. This resistance, now tested, could become a new support in case of consolidation. The stock is significantly above its 50-day (€2.66) and 200-day (€1.75) moving averages, a configuration that reflects a well-established upward trend in the medium and long term. The widening gap between these two moving averages, from €0.57 to €0.89 over the last twenty sessions, confirms the acceleration of the movement. The Bollinger Bands, which frame fluctuations between €2.22 and €3.77, show that the price reached the upper boundary on Wednesday, signaling a potential extension of volatility. The MACD, with a main line at 0.25 and a positive histogram at 0.08, indicates active buying momentum, although the money flows measured by the Chaikin Money Flow remain slightly negative at -0.05, suggesting persistent caution among some market participants. The negative beta of -0.21 further confirms that the stock moves in a manner uncorrelated with French stock indices, which could be a diversifying element for portfolios invested in specialized growth stocks.
